Memo Therapeutics AG

Memo Therapeutics AG is a late-stage biotech company headquartered in Schlieren, Switzerland, that specializes in developing best-in-class therapeutic antibodies. The company's focus is on transforming the lives of patients with viral infections and cancer. Their lead program, Potravitug, is a monoclonal antibody currently in Phase II development for the treatment of BK virus infection in kidney transplant recipients. This infection can lead to nephropathy, loss of kidney function, organ failure, and rejection.

Memo Therapeutics leverages its proprietary DROPZYLLA® technology platform to discover novel and potent antibodies. This technology enables the company to identify and isolate the most potent antibodies created by the body's immune response to viral infections and cancer. The company is actively pursuing both in-house programs and partnerships with pharmaceutical companies, such as Ono Pharmaceutical, to develop a diverse pipeline of antibody therapeutics for a range of diseases.

Memo Therapeutics AG is a late-stage biotech company dedicated to developing best-in-class therapeutic antibodies. Their mission is to change the standard of care for patients suffering from viral infections and cancer. They achieve this by leveraging natural human immune responses, specifically focusing on "elite responders" who have successfully fought off disease, to identify potent and targeted antibodies. Their lead program, Potravitug, is a highly potent antibody in Phase II development for treating BK virus infection in kidney transplant recipients, a condition with significant unmet need. Memo Therapeutics also actively pursues oncology programs, collaborating with Ono Pharmaceutical to discover novel antibody-target pairs for cancer treatment.

Memo Therapeutics AG promotes a collaborative and results-oriented culture that values scientific innovation and flawless execution. They foster a spirit of excellence through teamwork and a shared purpose, believing that success is achieved by working together and maintaining integrity in all interactions.

Memo Therapeutics AG is committed to fostering a diverse, equitable, and inclusive workplace where all employees feel valued, respected, and empowered to contribute their unique talents. They strive to create a culture of belonging by promoting collaboration and open communication, valuing different perspectives, and ensuring fair opportunities for all. Their efforts include attracting and retaining a diverse workforce, providing equal access to training and development opportunities, and creating a welcoming and inclusive environment for all.